The federal contract IDV award, valued at up to $499,999,999, is a single-award Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois. The contract was awarded by the Defense Logistics Agency (DLA) under the SPE2DB program, and it runs through December 31, 2025.
Under this IDC, DMS Pharmaceutical Group provides a comprehensive range of pharmaceutical products and medical supplies to fulfill the recurring medical needs of military healthcare facilities worldwide. The product portfolio includes branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, such as flumazenil injections, prednisone tablets, ampicillin injections, clotrimazole cream, epinephrine auto-injectors, contraceptives, oncology drugs, and specialty medications. These products are primarily delivered to the DLA's Medical Supply Chain division, which then distributes them to various Department of Defense (DoD) healthcare facilities globally. This IDC complements DMS Pharmaceutical Group's separate prime vendor contracts for direct distribution of prescription drugs and pharmacy services to DoD sites, solidifying the company's position as a crucial supplier in the federal pharmaceutical supply chain.
Generated 1/1/25, 9:05 AM